Year: 2026
Type: article
Abstract: OBJECTIVE: To assess outcomes of heavily treatment experienced people with HIV (PWH) who received the antiretroviral therapy salvage regimen containing raltegravir, etravirine, and darunavir/ritonavir (known as TRIO). METHODS: Data were from the ART Cohort Collaboration, which is a collaboration of European and North American HIV cohort studies. Adult PWH were eligible if they had a history of virologic failure while receiving nonnucleoside reverse-transcriptase inhibitors; three or more primary protease inhibitor and nucleoside reverse transcriptase inhibitor mutations; three or fewer darunavir and nonnucleoside reverse-transcriptase inhibitor mutations; received TRIO between 2007 and 2018; virologic failure at TRIO start; and did not receive any TRIO drugs previously. Follow-up began at TRIO start. We examined rates of virologic suppression on TRIO, AIDS/death, receipt of drug-reducing regimens post-TRIO in those virologically suppressed, and subsequent virologic response. We used a competing risks framework to estimate 5-y cumulative incidence of outcomes. RESULTS: Among 126 eligible PWH, 24% were female, and median age was 46 y (IQR: 41-50). Median follow-up was 7.9 y (IQR: 5.1-9.3). A total of 94 (74.6%) were virologically suppressed on TRIO. Of these, 26 (28%) subsequently switched to a drug-reducing regimen, of whom 19 of 26 (73.1%) were virologically suppressed at their next viral load measure. The 5-y cumulative incidence of outcomes was stop TRIO and start another three or more drug regimen (39.1%); simplify (16.0%); stop TRIO without switching (8.8%); and death on TRIO (7.2%). CONCLUSIONS: Although the most common outcome after TRIO was switch to another three or more drug regimen, almost one third of virologically suppressed PWH under TRIO (with a history of multidrug resistance) switched to a drug-reducing regimen, the majority of whom maintained suppression.
Authors: Suzanne M. Ingle, Fabrice Bonnet, Linda Wittkop, Alexandra Calmy, Ramon Teira, Peter F. Rebeiro, Heidi M. Crane, Christoph Stephan, Marc van der Valk, Christoph Boesecke, Giota Touloumi, M. John Gill, Katharina Grabmeier-Pfistershammer, Federico Garcia, Francesca Ceccherini-Silberstein, Greer Burkholder, Adam Trickey, Jonathan A.C. Sterne, Mojgan Hessamfar
Institutions: University of Bristol, Université de Bordeaux, Inserm, Centre Hospitalier Universitaire de Bordeaux, Bordeaux Population Health, Hôpital Saint-André, Institut national de recherche en sciences et technologies du numérique, SISTM: Statistics In System biology and Translational Medicine, University Hospital of Geneva, Hospital Sierrallana, Vanderbilt University, University of Washington, University Hospital Frankfurt, Stichting HIV Monitoring, Amsterdam University Medical Centers, Amsterdam institute for Immunology and Infectious Diseases, University of Amsterdam, University Hospital Bonn, National and Kapodistrian University of Athens, University of Calgary, Innsbruck Medical University, Instituto de Salud Carlos III, Instituto de Investigación Biosanitaria de Granada, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, University of Rome Tor Vergata, University of Alabama at Birmingham
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,280
Awards: Investigating the effect of climate extremes and global warming on HIV outcomes in sub-Saharan Africa, 1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VA, NIHR Senior Investigator Award, G4098140815, Investigating the effect of climate extremes and global warming on HIV outcomes in sub-Saharan Africa, A secure analytics platform to study the prognosis of people with HIV in the USA, Canada and Europe and comparative effectiveness of treatment regimens: the Antiretroviral Therapy Cohort Collaboration
OpenAlex ID: W7168210671